Using the DCA® Microalbumin/Creatinine (ACR) urine test on the DCA Vantage® Analyzer puts your practice on the front line of early kidney disease detection in patients with diabetes.
- ACR testing is recommended as an initial screening test for early detection of kidney disease by ADA, NKF, KDOQI, and KDIGO.
- The ADA recommends testing ACR annually in patients with type 1 diabetes (with diabetes duration >5 years) and in patients with type 2 diabetes.1
Features & Benefits
Deliver Optimal Diabetes Care with Improved Clinical Confidence
- Quantitative microalbumin/creatinine ratio (ACR) test results in minutes.
- Small sample volume—40 μL urine.
- Add sample to test cartridge, load, and walk away.
- No sample or reagent preparation required.
